Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul 9;56(1):2000962.
doi: 10.1183/13993003.00962-2020. Print 2020 Jul.

Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension

Bradley A Maron  1 , Marc Humbert  2
Affiliations
Editorial

Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension

Bradley A Maron et al. Eur Respir J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: B.A. Maron receives research funding from the NIH (NIH U01HL125215-01; R21HL134320; 1R01HL139613-01; U54HL119145), Cardiovascular Medical Research Education Foundation, and Boston Biomedical Innovation Center; is a co-inventor on US patent 9 605 047, US pending patent PCT/US2019/059890, and provisional patent applications 62475955 and 029672; and is a member of the steering committee for a research grant supported by Actelion Pharmaceuticals, outside the submitted work. Conflict of interest: M. Humbert reports grants and personal fees from Actelion, Bayer, GSK and Acceleron, personal fees from Merck and United Therapeutics, outside the submitted work.

Comment on

  • Pulmonary arterial hypertension with below threshold pulmonary vascular resistance.
    Ratwatte S, Anderson J, Strange G, Corrigan C, Collins N, Celermajer DS, Dwyer N, Feenstra J, Keating D, Kotlyar E, Lavender M, Whitford H, Whyte K, Williams T, Wrobel JP, Keogh A, Lau EM; PHSANZ Registry. Ratwatte S, et al. Eur Respir J. 2020 Jul 9;56(1):1901654. doi: 10.1183/13993003.01654-2019. Print 2020 Jul. Eur Respir J. 2020. PMID: 32341105

References

    1. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017;50(2). - PubMed
    1. Maron BA, Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol 2016;1(9):1056–1065. - PMC - PubMed
    1. D’Armini AM, Ghofrani HA, Kim NH, et al. Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. J Heart Lung Transplant 2015;34:348–55. - PubMed
    1. Maron BA, Hess E, Maddox TM, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation 2016;133(13):1240–8. - PMC - PubMed
    1. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888–894. - PubMed